Marisa Montes

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Paul E. Sax, Anton Pozniak, Marisa Montes et al. · The Lancet · 2017 · 395 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain

Deanna Kerrigan, Andrea Mantsios, Miguel Górgolas et al. · PLoS ONE · 2018 · 175 citations · Full text

Public Health, Health Behavior, Pharmacotherapy +17

Sustained Virological Response to Interferon Plus Ribavirin Reduces Non-Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus

Juan Berenguer, Elisa Boucourt Rodríguez, Pilar Miralles et al. · Clinical Infectious Diseases · 2012 · 166 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance of HIV-1 Viral Suppression

José Ramón Arribas, Federico Pulido, Rafaël Delgado et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2005 · 149 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Lopinavir-Ritonavir Monotherapy Versus Lopinavir-Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week Analysis

José Ramón Arribas, Rafaël Delgado, Alberto Arranz et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2009 · 108 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17